Topical Immunotherapy: A Breakthrough for Precancerous Skin Lesions
Skin cancer is increasingly becoming a health concern worldwide. With rising incidence rates, researchers are driven to explore innovative treatments. A remarkable approach attracting attention is topical immunotherapy, specifically the combination of calcipotriol and 5-fluorouracil (5-FU). Recent findings published in the Journal of Clinical Immunology illuminate the underlying biological mechanisms that render this therapy so effective.
Immunotherapy and Its Promising Role in Skin Cancer
Cancer immunotherapy has revolutionized treatment modalities, offering hope for many patients. However, it often comes with a hefty price tag and severe side effects, limiting its accessibility. These challenges have accelerated the quest for more affordable and less toxic alternatives.
Squamous cell carcinoma (SCC), the second most prevalent form of skin cancer, is particularly responsive to immune interventions, even during its precancerous stages. Actinic keratosis (AK), a condition that poses a risk for developing into SCC, can be effectively treated to diminish this risk. Various treatments like topical 5-FU, photodynamic therapy, imiquimod, and tirbanibulin are currently used to combat AK. Yet, only 5-FU has shown a slight, short-term reduction in SCC risk, a benefit that diminishes within two years.
Enter the innovative calcipotriol-plus–5-FU immunotherapy. Prior studies demonstrated its effectiveness in reducing AK lesions, but its biological mechanism remained elusive. Calcipotriol, akin to vitamin D and primarily used for psoriasis treatment, increases levels of thymic stromal lymphopoietin (TSLP) in skin cells. Combined with 5-FU, this reaction leads to a significant infiltration of immune cells into the lesions. This process forms tissue-resident memory T cells (TRM), offering prolonged immune protection. Impressively, calcipotriol-plus–5-FU therapy not only reduces SCC incidence over three years but does so without widespread negative effects. The latest research aims to decode the specific biological pathways powering this promising treatment.
Study Overview
The research involved 18 patients with AK who applied 0.0025% calcipotriol-plus–2.5% 5-FU daily for six days. Lesion status was stringently assessed through clinical evaluations and biopsies conducted pre-treatment and at intervals post-treatment. The treatment initially caused intense redness around the AKs, which subsided by eight weeks, demonstrating a considerable reduction in AK numbers.
On facial areas, AKs decreased by 95%, completely clearing in 70% of participants. Scalp lesions saw an 82% reduction, while upper limb lesions decreased by around 65-68% on both sides. These results indicate a strong response to the treatment, highlighting its potential as an effective skin cancer prevention strategy.
Enhancing Th2 Cell Activation
The application of calcipotriol-plus–5-FU resulted in a notable infiltration of CD4+ Th2 cells into the AKs while sparing unaffected skin. This outcome was accompanied by an increase in TRM cells, signifying the dominance of Th2 cell induction.
Calcipotriol prompts cytokine production, elevating TSLP levels. It activates immune stimulants such as damage-associated molecular patterns (DAMPs) and human leukocyte antigen class II (HLA-II) within precancerous skin cells. This activation is crucial, as it spares normal skin yet induces the immune response necessary for effective treatment. The Th2 polarization of CD4+ T cells, driven by TSLP, is pivotal in the therapy's success.
Understanding the Th2/IL-24 Axis
The upsurge in TSLP activates CD4+ Th2 cells to produce interleukin-24 (IL-24), a potent mediator that promotes cell death through toxic processes like autophagy and anoikis. These processes disrupt cells by causing self-digestion and loss of adhesion, ultimately leading to apoptosis or programmed cell death.
IL-24 further enhances the activity of enzymes like MMP-1, which disintegrates structural connections within the skin, culminating in cell death. This Th2-driven immune mechanism is vital in preventing cancer progression, and the T-cell immunity generated from this treatment lasts over five years, sustaining the fight against SCC by targeting AKs.
In studies, elimination of CD4+ T cells removed the protective benefits of the calcipotriol-plus–5-FU combination, signifying their critical role. This combination far exceeds the efficacy of either calcipotriol or 5-FU alone, especially in reducing tumor growth and delaying cancer onset, showcasing the importance of their synergy.
Concluding Insights
For the first time, this research reveals that Th2 polarization, activated by calcipotriol-plus–5-FU therapy, plays a crucial role in cancer prevention. The Th2/IL-24 pathway emerges as a promising target for future cancer therapies, with IL-24 acting as a principal agent in autophagy and apoptosis, extending its impact beyond individual tumors to a broader antitumor effect.
CD4+ T cells, central to adaptive immunity, are fundamental in activating tumor antigens. Their engagement is beneficial in addressing early-stage carcinomas and precancerous alterations. The enduring protection offered by this topical immunotherapy, facilitated by TSLP induction, reinforces its capability to delay and potentially prevent the transition from AK to SCC. As such, this research represents a significant leap forward in the fight against skin cancer, providing hope for more effective and less burdensome treatment options.
This transformative study, led by experts in the field, marks a significant step toward innovative cancer treatment, with lasting implications for managing precancerous conditions and preventing progression to invasive cancers.
출처 : Original Source